The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

4 1. Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years ...

ZORYVE cream 0.15% was approved by the FDA for the treatment of mild to moderate atopic dermatitis in individuals ages 6 and ...

While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of ...

The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...

Organon , a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months ...

cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of ...